Blood‐based biomarkers of Alzheimer's disease: Standardization and comprehensiveness
Abstract Population aging is sweeping across the globe, resulting in a striking prevalence of Alzheimer's disease (AD) and dementia and a heavy economic burden. Given the time window of 10–20 years from pathological initiation to clinically detected cognitive impairment, early detection can sig...
Saved in:
| Main Authors: | Ying Liu, Yu Guo, Jintai Yu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Neuroprotection |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/nep3.58 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications
by: Sarrah E. Ankeny, et al.
Published: (2024-09-01) -
Older US adults’ experiences with and views about cognitive screening and blood biomarker testing for Alzheimer's disease
by: Chelsea G. Cox, et al.
Published: (2025-01-01) -
Cerebrospinal Fluid Biomarkers of Alzheimer Disease
by: Kseniya V. Nevzorova, et al.
Published: (2025-06-01) -
Blood biomarkers as surrogate endpoints in Alzheimer’s disease research
by: Guogen Shan, et al.
Published: (2025-05-01) -
Translational opportunities and barriers for blood-based biomarkers in Alzheimer’s disease: from discovery to implementation
by: WANG Yanjiang, et al.
Published: (2025-08-01)